Apotex Cleared Of Amgen Infringement Claims In Fla. Suit

By Melissa Daniels (September 6, 2016, 9:07 PM EDT) -- A Florida federal judge on Tuesday cleared Canadian generics maker Apotex Inc. of patent infringement claims brought by pharmaceutical firm Amgen Inc. related to its blockbuster biologic Neulasta, saying that Amgen didn't prove how Apotex's biosimilars infringed but stopping short of awarding attorneys' fees. 

Amgen sued under the Biologics Price Competition and Innovation Act saying that Apotex infringed its U.S. Patent No. 8,952,138 covering a process of protein refolding with biosimilar versions of Neulasta and the related Neupogen, which are used in cancer patients.

After examining the manufacturing process for the Apotex biosimilars, U.S. District Judge James I. Cohn said that...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!